Skip Navigation

We are in clinical-stage immuno-oncology development today, targeting metastatic solid tumors. In the field of autoimmunity, we are using our proprietary platform to discover novel antigens and TCRs, starting with known and unique epitopes from Type 1 diabetes. We also are using our DECODE platform to develop immune medicines in infectious and autoimmune diseases, which are in discovery phase.